SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Human & Experimental Toxicology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Campbell, D.B.
Right arrow Articles by Ings, R.M.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Campbell, D.B.
Right arrow Articles by Ings, R.M.J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

New Approaches to the Use of Pharmacokinetics in Toxicology and Drug Development

D.B. Campbell

Servier Research and Development Ltd., Fulmer Hall, Windmill Road, Fulmer, Slough SL3 6HH, UK

R.M.J. Ings

Servier Research and Development Ltd., Fulmer Hall, Windmill Road, Fulmer, Slough SL3 6HH, UK

1 The use of pharmacokinetics in toxicology, clinical pharmacology and in the individualization of dosage has been critically examined.

2 In toxicity studies, doses are given to animals with the aim of achieving substantially higher plasma levels than the therapeutic level in man. However, small animals have faster metabolic rates, shorter life spans and drug clearance is many fold faster than in man, and this difference may not be compensated for by simply mg per kg dosing. Since toxicity still occurs at these lower levels, it begs the question whether small animals require such high doses to produce toxic effects.

3 A literature survey revealed that only 5 to 31% of the papers studied attempt to relate activity with plasma levels. Examples are given of how such relationships can be used, as with p-fenfluramine, where by investigating individual responses using drug plasma levels as a probe, a greater understanding of eating disorders may be obtained. Also, with tertatolol its prolonged pharmacological activity (> 24 h) can be explained mathematically despite a plasma half-life of only 3 h.

4 The advantages and disadvantages of population kinetics are discussed in relation to its use in individualizing dosage, particularly in disease, its appreciation by pharmaceutical companies and regulatory authorities and the information which has been obtained so far.

5 It is of interest that one of the youngest of drug development disciplines, pharmacokinetics, is now one of the most important.

Human & Experimental Toxicology, Vol. 7, No. 5, 469-479 (1988)
DOI: 10.1177/096032718800700515


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement